



Corrigendum: Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents

Daniel A. Ladin¹, Eman Soliman^{1,2}, LaToya Griffin¹ and Rukiyah Van Dross^{1,3*}

¹Department of Pharmacology and Toxicology, Brody School of Medicine, East Carolina University, Greenville, NC, United States, ²Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt, ³Center for Health Disparities, East Carolina University, Greenville, NC, United States

Keywords: cannabinoids, cancer, *in vivo*, clinical studies, clinical trials, therapeutics, cancer models, endocannabinoids

A Corrigendum on

Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents

by Ladin D. A., Soliman E., Griffin L. and Van Dross R. (2016). *Front. Pharmacol.* 7:361. doi: 10.3389/fphar.2016.00361

OPEN ACCESS

Approved by:

Frontiers Editorial Office, Frontiers
Media SA, Switzerland

*Correspondence:

Rukiyah Van Dross
vandrossr@ecu.edu

Specialty section:

This article was submitted to
*Experimental Pharmacology and Drug
Discovery*,
a section of the journal
Frontiers in Pharmacology

Received: 29 June 2021

Accepted: 30 June 2021

Published: 16 July 2021

Citation:

Ladin DA, Soliman E, Griffin L and
Van Dross R (2021) Corrigendum:
Preclinical and Clinical Assessment of
Cannabinoids as Anti-Cancer Agents.
Front. Pharmacol. 12:732903.
doi: 10.3389/fphar.2021.732903

In the original article, the **Reference** for “Blazquez, C. et al. (2006)” was incorrectly written as “Naeem et al. (2006).” The correct and full citation is “Blázquez, C., Carracedo, A., Barrado, L., Real, P. J., Fernández-Luna, J. L., Velasco, G., Malumbres, M., Guzmán, M. (2006). Cannabinoid receptors as novel targets for the treatment of melanoma. *FASEB J.* 20, 2633–2635. 10.1096/fj.06-6638fje.”

In the original article, the **Reference** for “Velasco, G., (2016)” was incorrectly written as “Fujimura et al. (1989).” The correct and full citation is “Velasco, G., Hernandez-Tiedra, S., Davila, D., and Lorente, M. (2016). The use of cannabinoids as anticancer agents. *Prog. Neuropsychopharmacol. Biol. Psychiatry.* 64, 259–266. 10.1016/j.pnpbp.2015.05.010.”

In the original article, the **Reference** for “Salazar (2009)” was incorrectly written as “Jenkins, M.A., et al. (2006).” The correct and full citation is “Salazar, M., Carracedo, A., Salanueva, I. J., Hernandez-Tiedra, S., Lorente, M., Egia, A., Vazquez, P., Blazquez, C., Torres, S., Garcia, S., Nowak, J., Fimai, G. M., Piacentini, M., Cecconi, F., Pandolfi, P. P., Gonzalez-Feria, L., Iovanna, J. L., Guzman, M., Boya, P., and Velasco, G. (2009). Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. *J. Clin. Invest.* 119, 1359–1372. 10.1172/JCI37948.”

In the original article, the **Reference** for “McKallip (2005)” was incorrectly written as “Martin-Banderas et al. (2015).” The correct and full citation is “McKallip, R. J., Nagarkatti, M., and Nagarkatti, P. S. (2005). Delta-9- tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. *J. Immunol.* 174, 3281–3289. 10.4049/jimmunol.174.6.3281.”

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Copyright © 2021 Ladin, Soliman, Griffin and Van Dross. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.